This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
by Zacks Equity Research
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant
by Zacks Equity Research
Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant are included in this Analyst Blog.
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc. (GILD) and Medtronic plc (MDT), as well as two micro-cap stocks Cooper-Standard Holdings Inc. (CPS) and Rave Restaurant Group, Inc. (RAVE).
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?
by Harshit Gupta
BWAY stock continues to struggle near its IPO price despite growth. With rising revenues, global expansion and valuation concerns, is it a buy, hold or sell before earnings?
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
by Urmimala Biswas
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns.
The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic
by Zacks Equity Research
AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
by Urmimala Biswas
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
Company News for Feb 19, 2025
by Zacks Equity Research
Companies In The Article Are:NKE, CC, MDT, ETR
Empire State Manufacturing Increase More Than Expected
by Zacks Equity Research
Empire State Manufacturing Increase More Than Expected
Pre-Market for New Trading Week in the Green
by Mark Vickery
Compared with the past two weeks, we're a little quieter here in this holiday-shortened trading week.
Here's What Key Metrics Tell Us About Medtronic (MDT) Q3 Earnings
by Zacks Equity Research
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended January 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
by Zacks Equity Research
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.
Medtronic (MDT) Tops Q3 Earnings Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 2.21% and 0.43%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
ISRG Nears $600: Can the Stock Breach the Mark Again This Month?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend in the past six months on the back of robust da Vinci portfolio performance. The stock has also gained during the past month. Let's see if the trend might change.
SYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
by Indrajit Bandyopadhyay
Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy? Find out the key factors at play.
Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $92.20, denoting a +0.93% change from the preceding trading day.
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -1.02% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
by Urmimala Biswas
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Seeking Clues to Medtronic (MDT) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended January 2025.
MDT Stock Trades Cheaper Than Peers Ahead of Q3 Earnings: Time to Buy?
by Urmimala Biswas
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.
Medtronic (MDT) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
Medtronic (MDT) reachead $90.01 at the closing of the latest trading day, reflecting a -0.89% change compared to its last close.
Medtronic (MDT) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $91.69, denoting a +0.79% change from the preceding trading day.
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
by Urmimala Biswas
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.